ѻý

Your Brain on Psilocybin; Probiotics and Parkinson's; Alzheimer's Signaling

<ѻý class="mpt-content-deck">— News and commentary from the world of neurology and neuroscience
MedpageToday
Brain scan images with NeuroBreak in the center.

Your : an MRI study looked at brain connectivity 20 minutes, 40 minutes, and 70 minutes after people received either psilocybin or placebo. (Biological Psychiatry)

New research about the and may make inflammation an important target for Alzheimer's and other neurological diseases, an essayist argued. (STAT)

A common probiotic, and cleared pre-formed aggregates in a roundworm synucleinopathy model, which may have implications for Parkinson's disease. (Cell Reports)

Roche announced plans to aggressively price its (formerly RG7916) to challenge two of the world's most expensive medicines -- nusinersen (Spinraza) and the gene therapy onasemnogene abeparvovec (Zolgensma) -- if the drug is approved in May. (Endpoints News)

Is a missing piece of the Alzheimer's disease puzzle? (Science Translational Medicine)

An investigational drug that by triggering alpha-synuclein antibodies is starting a phase II trial, Affiris announced.

RimabotulinumtoxinB and drooling in older adults with Parkinson's disease and other disorders. (JAMA Neurology)

Are -- who are conscious, but sealed off from the rest of the world -- in a limbo of torture? (STAT)

Nerve ultrasound coupled with standard nerve conduction studies improved detection of . (Neurology)

Acute and decreased tremor amplitude. (Journal of Psychopharmacology)

Anaphylaxis was added to the list of possible infusion-related reactions on the .

CT angiography to was cost effective, a study in Radiology showed.

Children from showed lower cognitive test scores and smaller cortical volume than children from higher-income families in similar environments. (Nature Medicine)